ST3GAL5

Across TCGA pan-cancer cohorts, ST3GAL5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ST3GAL5 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ST3GAL5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ST3GAL5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where ST3GAL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.798	0.387	.002	16	view →
PDAC	OS	Tertile	III,IV	0.645	0.234	.024	6	view →
LSCC	DFS	Median	III,IV	0.333	0.809	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ST3GAL5–LUAD (OS)

Open the LUAD breakdown →